- Home
- TECX vs GPAT Comparison
TECX vs GPAT Comparison
Compare TECX & GPAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TECX
- GPAT
- Stock Information
- Founded
- TECX 2019
- GPAT 2020
- Country
- TECX United States
- GPAT United States
- Employees
- TECX N/A
- GPAT N/A
- Industry
- TECX
- GPAT
- Sector
- TECX
- GPAT
- Exchange
- TECX Nasdaq
- GPAT NYSE
- Market Cap
- TECX 334.4M
- GPAT 365.5M
- IPO Year
- TECX 2018
- GPAT 2024
- Fundamental
- Price
- TECX $19.76
- GPAT $10.45
- Analyst Decision
- TECX Buy
- GPAT
- Analyst Count
- TECX 6
- GPAT 0
- Target Price
- TECX $72.40
- GPAT N/A
- AVG Volume (30 Days)
- TECX 203.0K
- GPAT 198.3K
- Earning Date
- TECX 05-08-2025
- GPAT 01-01-0001
- Dividend Yield
- TECX N/A
- GPAT N/A
- EPS Growth
- TECX N/A
- GPAT N/A
- EPS
- TECX N/A
- GPAT 0.34
- Revenue
- TECX N/A
- GPAT N/A
- Revenue This Year
- TECX N/A
- GPAT N/A
- Revenue Next Year
- TECX N/A
- GPAT N/A
- P/E Ratio
- TECX N/A
- GPAT $30.28
- Revenue Growth
- TECX N/A
- GPAT N/A
- 52 Week Low
- TECX $1.40
- GPAT $9.98
- 52 Week High
- TECX $61.07
- GPAT $10.45
- Technical
- Relative Strength Index (RSI)
- TECX 49.14
- GPAT N/A
- Support Level
- TECX $17.56
- GPAT N/A
- Resistance Level
- TECX $21.99
- GPAT N/A
- Average True Range (ATR)
- TECX 1.96
- GPAT 0.00
- MACD
- TECX 0.21
- GPAT 0.00
- Stochastic Oscillator
- TECX 46.15
- GPAT 0.00
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
About GPAT GP-ACT III ACQUISITION CORP
GP-Act III Acquisition Corp is a blank check company.